Peptide LibrarySomapacitan dosage in published studies and labels
These are the doses used for Somapacitan in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Somapacitan has FDA-approved human dosages as Sogroya, given by subcutaneous injection once a week. Children aged 2.5 years and older are dosed by weight: 0.16 mg/kg once weekly for growth hormone deficiency and 0.24 mg/kg once weekly for short stature after being born small for gestational age, Noonan syndrome or idiopathic short stature. Adults with growth hormone deficiency start at 1.5 mg once weekly and are titrated against serum IGF-1 to at most 8 mg once weekly.
| Human dosing established | Yes |
|---|---|
| Route | Subcutaneous |
| Frequency | Once weekly |
| Duration studied | Continuous |
| Titration | Adults: start at 1.5 mg once weekly (1 mg from age 65 and in moderate hepatic impairment, 2 mg for women on oral oestrogen), then raise by about 0.5–1.5 mg every 2–4 weeks guided by clinical response and serum IGF-1 drawn 3–4 days after a dose; maximum 8 mg once weekly (4 mg in moderate hepatic impairment). Children: individualised by growth response. |
| Half-life | About 2 to 3 days in adults with growth hormone deficiency; about 34 hours in children with growth hormone deficiency at 0.16 mg/kg/week (Sogroya label) |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — Sogroya, paediatric growth hormone deficiencyFDA-approved label · FDA prescribing information | Children aged 2.5 years and older with growth failure due to inadequate secretion of endogenous growth hormone | 0.16 mg/kg of actual body weight | Subcutaneous, upper arms, thigh, abdomen or buttocks, rotating the site weekly | Once weekly | Individualised by growth response | In the label's 52-week phase 3 study (200 treatment-naive children), annualised height velocity was 11.2 cm/year with Sogroya and 11.7 cm/year with daily somatropin 0.034 mg/kg/day | SOGROYA (somapacitan-beco) injection — FDA prescribing information, DailyMed |
| FDA label — Sogroya, small for gestational age, Noonan syndrome, idiopathic short statureFDA-approved label · FDA prescribing information | Children aged 2.5 years and older born small for gestational age without catch-up growth by age 2, or with Noonan syndrome or idiopathic short stature | 0.24 mg/kg of actual body weight | Subcutaneous | Once weekly | Individualised by growth response | Linear growth | SOGROYA (somapacitan-beco) injection — FDA prescribing information, DailyMed |
| FDA label — Sogroya, adult growth hormone deficiencyFDA-approved label · FDA prescribing information | Adults with growth hormone deficiency | 1.5 mg to start (1 mg from age 65; 2 mg with oral oestrogen), titrated to a maximum of 8 mg | Subcutaneous | Once weekly | Continuous; titrated against clinical response and serum IGF-1 | Replacement of endogenous growth hormone | SOGROYA (somapacitan-beco) injection — FDA prescribing information, DailyMed |
Where sources disagree
- Children are dosed in mg/kg and adults in fixed milligrams. A paediatric per-kilogram figure applied to an adult gives a dose far above the adult starting dose of 1.5 mg once weekly.
- Somapacitan is a growth hormone analogue with a side chain that binds albumin, which is what slows its clearance. Its once-weekly doses do not convert to daily somatropin or to the other once-weekly products (somatrogon, lonapegsomatropin), which have labels of their own.
- The label does not recommend Sogroya in severe hepatic impairment, or for children with moderate hepatic impairment. It comes only in prefilled pens (5, 10 and 15 mg) and covers no anti-ageing or performance use.